Founded in 2020, Myricx Pharma is developing small molecule inhibitors that selectively target the human N-myristoyltransferases (NMT) in cancer. The company is also exploring potential applications across other diseases. Based on research from Imperial College London and the Francis Crick Institute, Myricx says it has uncovered one of the most promising new areas of biology; […]

View post to subscribe to site newsletter.

Founded in 2020 as a spin-off from VBI in Belgium, Animab builds on a proprietary platform technology that enables efficient generation of monoclonal antibodies to prevent intestinal infections in farm animals. This new class of orally administered antibodies is designed to improve the health and performance of animals by targeting specific disease-causing pathogens. The company […]

View post to subscribe to site newsletter.

Founded in 2019, Altay Therapeutics develops small molecule drugs for a wide range of diseases, with a focus on chronic liver diseases like liver fibrosis and liver cancer. The company’s small molecules have potent inhibitor activity against disease-causing transcription factors by disrupting their association with DNA, and according to the company have shown exceptional results […]

View post to subscribe to site newsletter.